Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)

Background Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2-29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. Methods In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. Results Patients had a sustainable virologic, immunologic and symptomatic recovery. Conclusions Favipiravir may be a prosiming drug for the treatment of SFTS.